Lightcast Discovery Developing Droplet-Based Single-Cell Screening Platform

Jul 17, 2024 | Huanjia Zhang

NEW YORK – Single-cell technology company Lightcast Discovery is developing a droplet-based platform that promises to enable high-throughput single-cell functional assays in a massively parallel fashion.

The Cambridge, UK-based company raised £38 million ($49 million) in Series B funding last year and recently opened an office and laboratory in the US.

Founded in 2019, Lightcast has been developing a droplet-based microfluidic platform that harnesses so-called optical electrowetting-on-dielectric (oEWOD) technology, according to Paul Steinberg, the firm's chief commercial officer.

‍

"Our aim is developing the platform to be as powerful as possible, which is not just the hardware itself but all of the reagents, the protocols that would be required [for the workflow], to be as push-button friendly as possible for our customers,"

‍

Read the full article here.

‍

‍

About Lightcast

Lightcast aims to unleash new capabilities within the single-cell analysis field by developing a more accessible, scalable, and flexible platform for scientists in basic, translational, and applied research. These capabilities will empower new biological discoveries and accelerate the development of novel drugs, therapies, and biologics. Founded in 2019 and based in Cambridge, UK, Lightcast has invented a technology that uses rays of light to control picoliter-scale droplets for functional analysis of individual cells. For more information, visit www.lightcast.bio.

‍